19 Nov2018
Written by . Posted in News
PRE-ANNOUNCEMENT JTC 2019
ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 29 funding organisations have agreed to launch the second Joint Transnational Call for collaborative innovative research projects in Personalised Medicine (PM). This represents the first of three potential additional calls not co-funded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.
The call is planned to be launched in
January 2019 with a submission deadline for pre-proposals in
March 2019. It is expected, that consortia invited for the full-proposal stage, will need to submit their proposal
on June 17th, 2019.
The available budget for this call is
30 Mio€ (approx.).
AIMS OF THE CALL
With its second transnational call, ERA PerMed will foster research and innovation activities building close linkages between basic biomedical research, clinical research, bioinformatics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications.
The overarching goal is to improve disease management, with better patient stratification, diagnostics and treatment protocols, and disease prevention. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the health care systems. Proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on optimisation of health care systems.
The overall objectives of the ERA PerMed call are (i) to support
translational research projects in the field of Personalised Medicine; (ii) to encourage and enable
interdisciplinary collaborations towards implementation of PM, in combining pre-clinical and/or clinical research with computational components and research on relevant ethical, legal and social aspects (ELSA) and/or research on the optimisation of the health care systems; (iii) to encourage
collaboration between academia (research teams from universities, higher education institutions, public research performing institutions),
clinical/public health research (research teams from hospital/ public health institutions, healthcare settings and other healthcare organisations) and private partners e.g.
SMEs[1] (Small and Medium-size Enterprises).
SCOPE OF THE CALL
Proposals
must be interdisciplinary and clearly demonstrate the potential impact in PM as well as
the added value of transnational collaboration.
The JTC2019 of ERA PerMed will comprise three Research Areas:
Each project proposal
MUST address
at least one module of Research Area 3 and
at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.
GENERAL (eligibility) CONDITIONS FOR APPLICATION
Joint research proposals may be submitted by applicants belonging to one the following categories (A, B and/or C), if eligible according to relevant regional/national funding organisations regulations for research funding:
- Academia (research teams working in universities, other higher education institutions) or research institutes;
- Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
- (Industry) Private partners, e.g. SMEs[2] (small and medium-size enterprises).
| Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual ERA PerMed funding organisation respective of the region/country from which applicants have applied. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “Contact details of participating members”). |
Only transnational projects will be funded.
Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call (see list below). All three legal entities must be independent from each other. The
maximum number of partners per pre-proposal is six though not more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).
Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such.
Maximum one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding.
The coordinator must be eligible to be funded by the participating funding organisations to this call.
At the full-proposal stage, a consortium might be increased up to seven partners in total only by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to coordinators invited for full-proposals submission.
| Number of partners in the proposal* |
Pre-proposal |
Full-proposal
(only by inclusion of one underrepresented country) |
| 3 |
4 |
5 |
6 |
7 |
| Maximum number of partners with own funding |
0 |
1 |
1 |
1 |
1 |
| Maximum number of partners per country |
1 |
2 |
2 |
2 |
2 |
* minimum 3 partners eligible for funding from three different countries participating to the call
ICPerMed Partnering tool
If you are looking for potential partners, please have a look also at the
ICPerMed Partnering Tool:
https://partnering.pt-dlr.de/ICPerMed
PARTICIPATING MEMBERS, ASSOCIATED COUNTRIES AND REGIONS
Austria, Belgium, Canada (Quebec), Denmark, Finland, France, Germany (Saxon), Greece, Hungary, Ireland, Israel, Italy (Lombardy, Tuscany), Latvia, Luxembourg, Norway, Poland, Romania, Spain (Catalonia, Navarre), Sweden and Turkey (contact list is provided in Annex 1).
| Please Note:
The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication.
Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.
Final call information is expected to be published on the ERA PerMed website by January 2019. |
Annex 1: CONTACT DETAILS OF PARTICIPATING MEMBERS
| Country |
Funding Organisation |
Contact point |
Email |
| AUSTRIA |
FWF |
Stephanie Resch
Iris Fortmann |
Stephanie.Resch@fwf.ac.at
Iris.Fortmann@fwf.ac.at |
| BELGIUM |
F.R.S.-FNRS |
Joël Groeneveld
Florence Quist |
joel.groeneveld@frs-fnrs.be
florence.quist@frs-fnrs.be |
| CANADA |
CIHR |
Ilana Gombos |
Ilana.Gombos@cihr-irsc.gc.ca |
| CANADA
(QUEBEC) |
FRQS |
Maxime Beaudoin |
Maxime.beaudoin@frq.gouv.qc.ca |
| DENMARK |
InnoFond |
Ejner Moltzen
Jens Peter Vittrup |
Ejner.moltzen@innofond.dk
Jens.peter.vittrup@innofond.dk |
| FINLAND |
AKA |
Sara Illman |
sara.illman@aka.fi |
| FRANCE |
ANR |
Monika Frenzel |
ERAPerMed@agencerecherche.fr |
| GERMANY |
BMBF/DLR |
Katja Kuhlmann
Petra Lüers |
katja.kuhlmann@dlr.de Petra.Lueers@dlr.de |
| GERMANY |
BMG/VDI/VDE |
Dr. Anne Dwertmann
Dr. Andrea Repen |
Anne.Dwertmann@vdivde-it.de
Andrea.Repen@vdivde-it.de |
| GERMANY (SACHSEN) |
SMWK |
Eva Damm
Gabriele Süptitz |
permed@smwk.sachsen.de |
| GREECE |
GSRT |
Georgia Kostopoulou |
g.kostopoulou@gsrt.gr |
| HUNGARY |
NKFIH |
Dr. Klára Horváth |
klara.horvath@nkfih.gov.hu |
| IRELAND |
HRB |
Dr Caitriona Creely |
ccreely@hrb.ie |
| ISRAEL |
CSO-MOH |
Yahaloma Gat |
y.gat@moh.gov.il |
| ITALY |
IT-MoH |
Dr. Gaetano Guglielmi
Dr. Maria Josè Ruiz Alvarez |
g.guglielmi@sanita.it
mj.ruizalvarez-esterno@sanita.it |
| ITALY (LOMBARDY) |
FRRB |
Carmen De Francesco
Paola Larghi
Paola Bello |
carmen.defrancesco@frrb.it
paola.larghi@frrb.it
paola.bello@frrb.it |
| ITALY (TUSCANY) |
TUSCREG |
Donatella Tanini
Teresa Vieri |
erapermed@regione.toscana.it |
| LATVIA |
VIAA |
Maija Bundule
Uldis Berkis |
Maija.Bundule@viaa.gov.lv
Uldis.Berkis@viaa.gov.lv |
| LUXEMBOURG |
FNR |
Marie-Claude Marx |
marie-claude.marx@fnr.lu |
| NORWAY |
RCN |
Karianne Solaas |
kso@rcn.no |
| POLAND |
NCBR |
Marcin Chmielewski |
marcin.chmielewski@ncbr.gov.pl |
| ROMANIA |
UEFISCDI |
Cristina Laura COTET |
cristina.cotet@uefiscdi.ro |
| SPAIN |
ISCIII |
Mauricio Garcia Franco
Eduard Güell Del Frago |
mauriciog@isciii.es
eguell@externos.isciii.es |
| SPAIN |
CDTI |
Sara Alfonso |
sara.alfonso@cdti.es |
| SPAIN |
AECC-FC |
Marta Puyol |
marta.puyol@aecc.es |
| SPAIN (CATALONIA) |
DS-CAT |
Montserrat Llavayol |
peris@gencat.cat |
| SPAIN (NAVARRE) |
GN |
Sara Torres |
storresl@navarra.es |
| SWEDEN |
SRC |
Malin Eklund |
Malin.Eklund@vr.se |
| TURKEY |
TUBITAK |
Banu Gökcay |
banu.buruk@tubitak.gov.tr |
[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en
[2] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en
Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.